Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182
|ClinicalTrials.gov Identifier: NCT01074398|
Recruitment Status : Unknown
Verified February 2010 by National Cancer Institute (NCI).
Recruitment status was: Not yet recruiting
First Posted : February 24, 2010
Last Update Posted : February 24, 2010
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.
PURPOSE: This research study is looking at biomarkers in predicting response in patients with advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
|Condition or disease||Intervention/treatment|
|Fallopian Tube Cancer Ovarian Cancer Peritoneal Cavity Cancer||Genetic: gene expression analysis Genetic: polymorphism analysis Genetic: protein expression analysis Other: immunohistochemistry staining method Other: laboratory biomarker analysis|
- To evaluate ERCC1 tumor expression, as measured by IHC, as a predictor of progression-free and overall survival of patients with advanced ovarian epithelial cancer.
- To correlate ERCC1 single-nucleotide polymorphisms (C8092A and codon 118) with ERCC1 tumor expression.
OUTLINE: This is a multicenter study.
Blood and paraffin-embedded tumor tissue samples are analyzed for ERCC1 tumor expression by IHC and single-nucleotide polymorphisms.
|Study Type :||Observational|
|Estimated Enrollment :||513 participants|
|Official Title:||ERCC1 Expression as a Predictor of Progression Free and Overall Survival in Patients With Epithelial Ovarian Cancer Treated on GOG Protocols 0172 and 0182|
|Study Start Date :||February 2010|
|Estimated Primary Completion Date :||March 2010|
- Association between ERCC1 tumor expression and progression-free and overall survival
- Association between ERCC1 polymorphisms and ERCC1 tumor expression
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01074398
|Study Chair:||Thomas C. Krivak, MD||University of Pittsburgh|